Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

Recent & Breaking News (TSX:GUD)

Notice of Knight Therapeutics' Fourth Quarter and Year End 2022 Results Conference Call

GlobeNewswire March 16, 2023

Knight Therapeutics (TSX:GUD) closes US$38.5 million loan with IFC

Azuka Onwuka December 23, 2022

Knight Therapeutics Closes US$38.5 million Loan with IFC

GlobeNewswire December 23, 2022

Knight Therapeutics (TSX:GUD) to relaunch AKYNZEO in Canada

Trevor Abes  December 1, 2022

Knight Announces Relaunch of AKYNZEO® in Canada

GlobeNewswire December 1, 2022

Knight Therapeutics Reports Third Quarter 2022 Results

GlobeNewswire November 10, 2022

Knight to Present at Stifel Healthcare Conference

GlobeNewswire November 9, 2022

Notice of Knight Therapeutics' Third Quarter 2022 Results Conference Call

GlobeNewswire November 3, 2022

Knight Therapeutics (TSX:GUD) announces regulatory filing for Tafasitamab in Brazil

Trevor Abes  October 7, 2022

Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil

GlobeNewswire October 6, 2022

Knight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of Canada's Top Growing Companies

GlobeNewswire September 23, 2022

Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil

GlobeNewswire August 15, 2022

Knight Therapeutics Reports Second Quarter 2022 Results

GlobeNewswire August 11, 2022

Knight to Present at the Canaccord Genuity 42nd Annual Growth Conference

GlobeNewswire August 4, 2022

Notice of Knight Therapeutics' Second Quarter 2022 Results Conference Call

GlobeNewswire August 4, 2022

Knight Therapeutics (TSX:GUD) announces NCIB

John Ballem  July 12, 2022

Knight Announces Normal Course Issuer Bid

GlobeNewswire July 12, 2022

Knight Therapeutics (TSX:GUD) relaunches AKYNZEO in Brazil

Trevor Abes  July 4, 2022

Knight Therapeutics announces relaunch of AKYNZEO® in Brazil

GlobeNewswire July 4, 2022

Knight to Present at the 2022 BIO International Convention in San Diego

GlobeNewswire June 7, 2022